Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke

Lucie A van den Berg*, Olvert A Berkhemer, Puck S S Fransen, Debbie Beumer, Hester Lingsma, Charles B M Majoie, Diederik W J Dippel, Aad van der Lugt, Robert J van Oostenbrugge, Wim H van Zwam, Yvo B Roos*, Marcel G W Dijkgraaf, MR CLEAN Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

59 Downloads (Pure)

Abstract

BACKGROUND AND PURPOSE: Endovascular treatment for acute ischemic stroke has been proven clinically effective, but evidence of the cost-effectiveness based on real-world data is scarce. The aim of this study was to assess whether endovascular therapy plus usual care is cost-effective in comparison to usual care alone in acute ischemic stroke patients.

METHODS: An economic evaluation was performed from a societal perspective with a 2-year time horizon. Empirical data on health outcomes and the use of resources following endovascular treatment were gathered parallel to the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) and its 2-year follow-up study. Incremental cost-effectiveness ratios were calculated as the extra costs per additional patient with functional independence (modified Rankin Scale score 0-2) and the extra cost per quality-adjusted life year gained.

RESULTS: The mean costs per patient in the intervention group were $126 494 versus $143 331 in the control group (mean difference, -$16 839 [95% CI, -$38 113 to $5456]). Compared with patients in the control group, more patients in the intervention group achieved functional independence, 37.2% versus 23.9% (absolute difference, 13.3% [95% CI, 4.0%-22.0%]) and they generated more quality-adjusted life years, 0.99 versus 0.83 (mean difference of 0.16 [95% CI, 0.04-0.29]). Endovascular treatment dominated standard treatment with $18 233 saved per extra patient with a good outcome and $105 869 saved per additional quality-adjusted life year.

CONCLUSIONS: Endovascular treatment added to usual care is clinically effective, and cost saving in comparison to usual care alone in patients with acute ischemic stroke.

REGISTRATION: URL: https://www.trialregister.nl/trial/695; Unique identifier: NL695. https://www.isrctn.com/ISRCTN10888758; Unique identifier: ISRCTN10888758.

Original languageEnglish
Article numberSTROKEAHA121034599
Pages (from-to)968-975
Number of pages8
JournalStroke
Volume53
Issue number3
Early online date14 Oct 2021
DOIs
Publication statusPublished - Mar 2022

Keywords

  • cost savings
  • follow-up studies
  • ischemic stroke
  • quality-adjusted life years
  • STENT-RETRIEVER THROMBECTOMY
  • COST-EFFECTIVENESS
  • TRIAL
  • DISEASE

Fingerprint

Dive into the research topics of 'Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke'. Together they form a unique fingerprint.

Cite this